Biotech · Public company · Philadelphia, PA, US
Passage BIO, Inc.
Ticker PASG · SEC CIK 0001787297
Track this companyFree. Adds Passage BIO, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials42 recruiting or active
Pipeline programs1From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline1
- PBFT02Phase 2 · Frontotemporal DementiaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 GenesPHASE1_PHASE2 · TERMINATED · started Sep 14, 2021ClinicalTrials.gov NCT04747431 · fetched Nov 12, 2026
- ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening ProgramENROLLING_BY_INVITATION · started May 10, 2021ClinicalTrials.gov NCT05368038 · fetched Nov 12, 2026
- Natural History Study of Infantile and Juvenile GM1 Gangliosidosis (GM1) PatientsCOMPLETED · started Jun 12, 2020ClinicalTrials.gov NCT04041102 · fetched Nov 12, 2026
- The Myelin Disorders Biorepository ProjectRECRUITING · started Dec 8, 2016ClinicalTrials.gov NCT03047369 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 3, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 10, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 24, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 27, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed May 26, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 12, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Apr 28, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Apr 20, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Mar 10, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 3, 2026 · fetched Nov 12, 2026